<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00158691</url>
  </required_header>
  <id_info>
    <org_study_id>GORTEC 2000-02</org_study_id>
    <nct_id>NCT00158691</nct_id>
  </id_info>
  <brief_title>Intravenous Versus Subcutaneous Amifostine in Prevention of Xerostomia After RT for Head and Neck Carcinomas</brief_title>
  <official_title>A Randomized Phase III Study Comparing Intravenous Versus Subcutaneous Administration of Amifostine in Prevention of Xerostomia for Patients Receiving Radiotherapy for Head and Neck Carcinomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Oncologie Radiotherapie Tete et Cou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Oncologie Radiotherapie Tete et Cou</source>
  <brief_summary>
    <textblock>
      Prospective randomized study in order to compare intravenous versus subcutaneous
      administration of amifostine in patients receiving radiotherapy for head and neck cancer.
      Salivary flow will be evaluated during few years after the treatment by a clinical
      evaluation, the measure of the weight of saliva and a patient benefit questionnaire cotation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective randomized study in order to compare intravenous (IV) versus subcutaneous (SC)
      administration of amifostine in patients receiving radiotherapy for head and neck cancer. IV
      administration of amifostine is 200 mg/m2/day in a short 3-min infusion 15 to 30 min before
      each fraction of radiotherapy. SC administration is 500mg/day in two slow 1.25 ml injections
      at two different sites 20 to 60 min before each radiotherapy fraction. Procedure requires
      antiemetic treatment and blood pressure monitoring in both arms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2001</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late xerostomia rate</measure>
  </primary_outcome>
  <enrollment>296</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethyol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  newly diagnosed squamous cell head and neck cancer

          -  inclusion of at least 75% of both parotid glands within radiation fields that would
             receive at least 40 Gy

          -  Neutrophils ≥ 2000 / mm, Platelets ≥ 100,000 / mm3, Creatinine &lt; 130 / mmol.L-1,
             Transaminase ≤ 3 x upper limit

        Exclusion Criteria:

          -  Distant metastases

          -  Prophylactic use of pilocarpine

          -  Concomitant chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Etienne Bardet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Régional de Lutte contre le Cancer de Nantes-Atlantique</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Régional de Lutte contre le Cancer de Nantes-Atlantique</name>
      <address>
        <city>Nantes</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.gortec.org</url>
  </link>
  <reference>
    <citation>Bardet E, Martin L, Calais G, Tuchais C, Bourhis J, Rhein B, Feham N, Alphonsi M. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Semin Oncol. 2002 Dec;29(6 Suppl 19):57-60.</citation>
    <PMID>12577246</PMID>
  </reference>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>September 8, 2005</last_update_submitted>
  <last_update_submitted_qc>September 8, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2005</last_update_posted>
  <keyword>Head and Neck cancer</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Xerostomia</keyword>
  <keyword>Randomized trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Xerostomia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amifostine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

